As middle ear infections increase during the winter months, researchers from Ben-Gurion University of the Negev (BGU) suggest that in many cases the most appropriate treatment is “watchful waiting” instead of using antibiotics immediately.
The review, published in the scientific journal Expert Review of Anti-Infective Therapy, does not suggest use of watchful waiting in all cases when the infection, also known as Acute Otitis Media (AOM), is suspected by a pediatrician, but notes that a large majority of cases can be treated this way with no long-term ill effects. Currently, watchful waiting is recommended for children over six months of age with mild to moderate symptoms or an uncertain AOM diagnosis.
The authors indicate that watchful waiting could substantially reduce the use of antibiotics in the treatment of AOM and play a major role in helping fight the development of treatment-resistant bacteria. (See table below for complete list of initial treatment recommendations).
“For years, antibiotic therapy was the norm for any child presenting with AOM symptoms,” said Dr. Eugene Leibovitz, lead author of the review, who is a BGU professor and works in the Pediatric Infectious Diseases unit at Soroka University Medical Center. “However, we soon learned that there are problems with this strategy. While the antibiotics were killing off most of the AOM-causing bacteria, the few bacteria that managed to survive have developed resistance to that treatment.”
The review notes that since the introduction of a polysaccharide conjugate vaccine to prevent infections from seven serotypes of the bacteria named Streptococcus pneumoniae, the number of AOM infections associated with these bacteria has decreased. However, AOM infections from bacteria not covered by the vaccine are on the rise. A new vaccine, one that prevents infections caused by 13 serotypes of S. pneumoniae, was recently introduced in routine use in many countries.
“Appropriate antibiotic treatment and vaccine-resistant bacteria remain a problem in managing children with AOM,” said Leibovitz. “With selective guidelines-recommended use of antibiotic therapies and employing watchful waiting in non-critical cases, hopefully, we can discourage the emergence of other treatment-resistant bacterial strains.”
Leibovitz E, Broides A, Greenberg D, Newman N.
Expert Rev Anti Infect Ther. 2010 Feb;8 (2):151-61.
About American Associates, Ben-Gurion University of the Negev
American Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion’s vision, creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University’s expertise locally and around the globe. With some 20,000 students on campuses in Beer-Sheva, Sede Boqer and Eilat in Israel’s southern desert, BGU is a university with a conscience, where the highest academic standards are integrated with community involvement, committed to sustainable development of the Negev. AABGU is headquartered in Manhattan and has nine regional offices throughout the U.S.
Contact: Andrew Lavin
American Associates, Ben-Gurion University of the Negev